Interleukin-31
(IL-31) is a major protein involved in severe inflammatory
skin disorders. Its signaling pathway is mediated through two type
I cytokine receptors, IL-31RA (also known as the gp130-like receptor)
and the oncostatin M receptor (OSMR). Understanding molecular details
in these interactions would be helpful for developing antagonist anti-IL-31
monoclonal antibodies (mAbs) as potential therapies. Previous studies
suggest that human IL-31 binds to IL-31RA and then recruits OSMR to
form a ternary complex. In this model, OSMR cannot interact with IL-31
in the absence of IL-31RA. In this work, we show that feline IL-31
(fIL-31) binds independently with feline OSMR using surface plasmon
resonance, an enzyme-linked immunosorbent assay, and yeast surface
display. Moreover, competition experiments suggest that OSMR shares
a partially overlapping epitope with IL-31RA. We then used deep mutational
scanning to map the binding sites of both receptors on fIL-31. In
agreement with previous studies of the human homologue, the binding
site for IL31-RA contains fIL-31 positions E20 and K82, while the
binding site for OSMR comprises the “PADNFERK” motif
(P103–K110) and position G38. However, our results also revealed
a new overlapping site, composed of positions R69, R72, P73, D76,
D81, and E97, between both receptors that we called the “shared
site”. The conformational epitope of an anti-feline IL-31 mAb
that inhibits both OSMR and IL-31RA also mapped to this shared site.
Combined, our results show that fIL-31 binds IL-31RA and OSMR independently
through a partially shared epitope. These results suggest reexamination
of the putative canonical mechanisms for IL-31 signaling in higher
animals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.